Christopher J. Winrow

Christopher Winrow has a diverse range of work experience in the pharmaceutical and biotech industry. Christopher is currently the Chief Scientific Officer at Lucy Therapeutics, a position they have held since March 2023. Before joining Lucy Therapeutics, they worked at Cyclerion in various roles. From April 2021 to October 2022, they served as the Vice President and Head of Translational Medicine, responsible for developing and implementing biomarker strategies for clinical development in multiple therapeutic areas. Prior to that, they were the Head of Translational Medicine from December 2020 to April 2021 and the Senior Director of Clinical Development - Neuroscience Program Lead from April 2019 to December 2020.

Before their time at Cyclerion, Christopher Winrow worked at Ironwood Pharmaceuticals as a Senior Principal Investigator from November 2016 to March 2019. In this role, they led multidisciplinary teams and collaborated with internal and external stakeholders to develop and execute program strategies for clinical-stage compounds.

Their earlier experience includes roles at Merck & Co., Inc. where they served as a Director from May 2009 to November 2016, playing a key role in leading the Discovery Team for Belsomra® and advancing compounds for CNS therapeutic. Christopher also held positions as a Research Fellow and Senior Research Biologist at Merck.

Christopher Winrow's career began at the Salk Institute for Biological Studies, where they worked as a Postdoctoral Fellow from February 1999 to July 2002, focusing on the evaluation of genomic loci for genes involved in neurodegeneration.

Christopher Winrow holds a Ph.D. in Cell Biology from the University of Alberta. Prior to that, they pursued their undergraduate studies at McMaster University, where they earned a B.Sc. (Honors) in Molecular Biology.